Want to take Stockholm3?
Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, a number of healthcare providers offer Stockholm3.
-
75000
Participants in clinical studies
-
100 %
More cases of aggressive cancers found
-
50 %
Fewer unnecessary biopsies
-
17-28 %
Reduced healthcare costs
Stockholm3
A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.
Press releases
-
The European Commission recommends member states to implement organized screening of prostate cancer
September 26, 2022
-
A3P Biomedical forms Scientific Advisory Board
August 31, 2022
-
Stockholm3 in NICE Medtech Innovation Briefing for the UK
August 23, 2022